Request Trial
brexit_istock-531915594_altamira83
altamira83 / iStockphoto.com
19 November 2018Pharma

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

The UK has an excellent opportunity to adopt laws on supplementary protection certificates (SPCs) that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Behind the case: How Novartis defended its blockbuster Entresto in the UK
22 September 2026   After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling.
Pharma
Non-profit sues Cambrex over anticancer drug manufacturing trade secrets
17 September 2026   Bauer Research Foundation has alleged that the CDMO misappropriated its confidential manufacturing know-how related to NO-Cbl, an anticancer drug candidate in the pre-clinical/translational stage of development for potential human use.
Pharma
Beyond the primary patent: How pharma can build competitive barriers
16 September 2026   A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

More features

Behind the case: How Novartis defended its blockbuster Entresto in the UK
Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight
Benesch adds former McDermott IP practice head
Leading European patent litigator to join Carpmaels & Ransford
CIPA Congress: Sustainability is essential for the profession and the planet
Non-profit sues Cambrex over anticancer drug manufacturing trade secrets
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Amgen hit with lawsuit over its proposed Opdivo biosimilar